Jason Coloma, Maze Therapeutics CEO
December 3, 2024 09:07 AM EST
Financing
Startups

Af­ter deal about-face and a spin­out, Maze as­sem­bles $115M Se­ries D

Kyle LaHucik

Senior Reporter

Bay Area biotech Maze Ther­a­peu­tics said Tues­day it com­plet­ed a $115 mil­lion Se­ries D, weeks af­ter split­ting off some of its ALS …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Up­dat­ed: Bay Area biotech VC to shut down 15 months af­ter launch, sources say, af­ter key in­vestor pulls out

Ma­jor FDA staff cuts would slow drug re­views, ex­perts say

Bris­tol My­ers prunes pipeline amid new round of cost cuts

Trump 2.0 blog: Thou­sands of fed­er­al health work­ers could get axed, ac­cord­ing to re­ports

Sen­a­tors ask FDA to dig in­to 'mis­lead­ing' Su­per Bowl ad from Hims

Up­dat­ed: Lil­ly posts 45% sales jump, culls four pro­grams across obe­si­ty, Alzheimer's, heart fail­ure and eczema

A service from the Financial Times